Correction: Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial

Atsumi T, Tanaka Y, Yamamoto K, et al. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Ann Rheum Dis 2017;76:1348–56. doi:10.1136/annrheumdis-2016-210246.

There are some minor errors in the numbers report in table 1. The correct values are:

Table 1 Baseline demographics and patient characteristics

|                  | CZP+MTX® | PBO+MTX® | MTX PBO+MTX® | MTX | PBO | MTX  |
|------------------|----------|----------|--------------|-----|----|------|
|                  | n=159    | n=108    | n=157        | n=71|     | n=71 |
|                  | DB baseline(Week 0) | DB baseline(Week 0) | PT baseline(Week 52) | DB baseline(Week 0) | DB baseline(Week 0) | PT baseline(Week 52) |
| Age (years)      | 49.4±10.6 | 48.8±11.2 | – | 49.0±10.3 | 48.6±10.8 | – |
| Female, n (%)    | 129 (81.1) | 85 (78.7) | – | 127 (80.9) | 58 (81.7) | – |
| Weight (kg)      | 57.4±11.3 | 57.0±11.5 | – | 57.4±10.6 | 57.4±10.3 | – |
| BMI (kg/m²)      | 22.4±3.9 | 22.2±3.7 | – | 22.5±3.7 | 22.4±3.7 | – |
| RA duration (months)* | 4.0±2.9 | 4.4±3.1 | – | 4.3±2.8 | 4.4±3.1 | – |
| Anti-CCP antibody positive, n (%) | 159 (100.0) | 108 (100.0) | – | 157 (100.0) | 71 (100.0) | – |
| RF positive, n (%) | 153 (96.2) | 104 (96.3) | – | 146 (93.0) | 68 (95.8) | – |
| Bone erosion (judged by physician), n (%) | 79 (49.7) | 51 (41.7) | – | 80 (51.0) | 34 (47.9) | – |
| TJC (/28 joints) | 8.4±6.1 | 7.5±5.8 | 0.5±1.1 | 8.9±6.5 | 7.3±6.1 | 0.6±1.6 |
| SJC (/28 joints) | 8.3±5.3 | 7.6±4.6 | 0.3±0.7 | 8.4±5.3 | 7.0±4.2 | 0.4±1.4 |
| ESR (mm/h)       | 38.4±25.3 | 36.3±23.7 | 12.8±9.9 | 43.7±28.2 | 35.9±22.2 | 15.3±14.3 |
| CRP (mg/dl)      | 1.2±1.82 | 1.1±1.51 | 0.06±0.13 | 1.3±1.91 | 1.0±1.39 | 0.1±0.37 |
| MMP-3 (ng/ml)    | 130.4±135.4 | 125.3±135.4 | 47.7±25.7 | 185.4±214.9 | 167.3±204.3 | 53.5±37.1 |
| DAS28 (ESR)      | 5.4±1.1 | 5.2±1.1 | 1.9±0.8 | 5.5±1.2 | 5.1±1.0 | 2.0±0.7 |
| SDI               | 28.7±12.5 | 27.0±11.2 | 2.4±2.6 | 30.0±13.6 | 24.6±11.3 | 2.7±3.1 |
| HAQ-DI score     | 1.0±0.64 | 1.0±0.63 | 0.14±0.26 | 1.0±0.69 | 0.7±0.57 | 0.07±0.14 |
| nTSS              | 4.1±7.4 | 3.8±7.4 | 3.7±4.7 | 5.5±15.0 | 3.2±6.2 | 3.4±6.3 |
| Erosion score    | 1.5±4.0 | 1.6±3.9 | 1.6±3.7 | 2.5±7.8 | 1.6±3.3 | 1.8±3.2 |
| Joint space narrowing score | 2.1±4.6 | 2.2±4.8 | 2.2±4.8 | 2.9±8.3 | 1.5±4.0 | 1.6±4.1 |
| Average weekly MTX dose (mg/week)* | 11.4±2.1 | 11.3±2.2 | 10.9±4.1 | 11.5±2.8 | 11.5±3.1 | 11.1±2.7 |

Values are mean ±SD unless otherwise indicated. Data in DB baseline columns represent average during weeks 0–104, whereas data in PT baseline columns represent average during weeks 52–104.

*Time from onset of persistent arthritic symptoms.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.